BioCentury | Nov 4, 2016
Strategy

The next (re)generation

...continuation. The company announced plans to merge with robotics company Microbot Medical Ltd. in August. Macrocure Ltd....
...Los Angeles, Calif. Leap Therapeutics Inc., Cambridge, Mass. London Project to Cure Blindness, London, U.K. Macrocure Ltd....
...Institute for Regenerative Medicine (CIRM) Charles River Laboratories International Inc. City of Hope Fate Therapeutics Inc. Harvard University Leap Therapeutics Inc. Macrocure Ltd. Massachusetts...
BioCentury | Oct 24, 2016
Clinical News

DKN-01: Phase I data

...presented at the European Society for Medical Oncology meeting in Copenhagen. Leap is merging with Macrocure Ltd....
BioCentury | Sep 5, 2016
Company News

Leap Therapeutics, Macrocure deal

...Leap will merge with Macrocure in a deal that will create a publicly listed company with...
...TNFR)-related protein (GITR; TNFRSF18 ), is in Phase I development for solid tumors. Last August, Macrocure...
...treat venous leg ulcers. Leap shareholders will own about 68% of the combined company and Macrocure...
BioCentury | Aug 29, 2016
Company News

Leap merging with Macrocure

...Leap Therapeutics Inc. (Cambridge, Mass.) is merging with Macrocure Ltd. (NASDAQ:MCUR) in a deal that will create...
...development for solid tumors. Leap shareholders will own about 68% of the combined company and Macrocure...
...will invest $10 million in the merged company. Raymond James is advising Macrocure. Last August, Macrocure's...
BioCentury | Nov 9, 2015
Clinical News

CureXcell: Phase III data

...for 4 additional weeks and with >=50% target ulcer closure during treatment vs. sham controls. Macrocure Ltd....
BioCentury | Oct 5, 2015
Finance

Drawn and quartered

...NASDAQ:KPTI) Selinexor fails in the Phase II SOPRA trial to treat acute myelogenous leukemia (AML) Macrocure Ltd....
BioCentury | Aug 24, 2015
Analyst Picks & Changes

Analyst picks & changes

...4Q15 a Phase III trial of the ATP citrate lyase (ACLY) inhibitor in the indication. Macrocure Ltd....
...said the futility finding is "surprising" given the "healthy real world" experience in Israel, where Macrocure...
BioCentury | Aug 24, 2015
Clinical News

CureXcell: Phase III data

...a Phase III trial of CureXcell to treat diabetic foot ulcers are expected in October. Macrocure...
BioCentury | Aug 21, 2015
Company News

Macrocure plunges on Phase III futility analysis

Macrocure Ltd. (NASDAQ:MCUR) lost $9.07 (75%) to $2.98 on Thursday following its disclosure after market on Wednesday that a futility analysis showed CureXcell was unlikely to meet the primary endpoint of the Phase III MC-105...
BioCentury | Aug 20, 2015
Clinical News

Macrocure says CureXcell likely to fail in Phase III

...100% wound closure at 12 weeks and sustained complete closure for four additional weeks (p≤0.05). Macrocure...
...containing activated allogeneic white blood cells isolated from the peripheral blood of healthy allogeneic donors. Macrocure...
Items per page:
1 - 10 of 20
BioCentury | Nov 4, 2016
Strategy

The next (re)generation

...continuation. The company announced plans to merge with robotics company Microbot Medical Ltd. in August. Macrocure Ltd....
...Los Angeles, Calif. Leap Therapeutics Inc., Cambridge, Mass. London Project to Cure Blindness, London, U.K. Macrocure Ltd....
...Institute for Regenerative Medicine (CIRM) Charles River Laboratories International Inc. City of Hope Fate Therapeutics Inc. Harvard University Leap Therapeutics Inc. Macrocure Ltd. Massachusetts...
BioCentury | Oct 24, 2016
Clinical News

DKN-01: Phase I data

...presented at the European Society for Medical Oncology meeting in Copenhagen. Leap is merging with Macrocure Ltd....
BioCentury | Sep 5, 2016
Company News

Leap Therapeutics, Macrocure deal

...Leap will merge with Macrocure in a deal that will create a publicly listed company with...
...TNFR)-related protein (GITR; TNFRSF18 ), is in Phase I development for solid tumors. Last August, Macrocure...
...treat venous leg ulcers. Leap shareholders will own about 68% of the combined company and Macrocure...
BioCentury | Aug 29, 2016
Company News

Leap merging with Macrocure

...Leap Therapeutics Inc. (Cambridge, Mass.) is merging with Macrocure Ltd. (NASDAQ:MCUR) in a deal that will create...
...development for solid tumors. Leap shareholders will own about 68% of the combined company and Macrocure...
...will invest $10 million in the merged company. Raymond James is advising Macrocure. Last August, Macrocure's...
BioCentury | Nov 9, 2015
Clinical News

CureXcell: Phase III data

...for 4 additional weeks and with >=50% target ulcer closure during treatment vs. sham controls. Macrocure Ltd....
BioCentury | Oct 5, 2015
Finance

Drawn and quartered

...NASDAQ:KPTI) Selinexor fails in the Phase II SOPRA trial to treat acute myelogenous leukemia (AML) Macrocure Ltd....
BioCentury | Aug 24, 2015
Analyst Picks & Changes

Analyst picks & changes

...4Q15 a Phase III trial of the ATP citrate lyase (ACLY) inhibitor in the indication. Macrocure Ltd....
...said the futility finding is "surprising" given the "healthy real world" experience in Israel, where Macrocure...
BioCentury | Aug 24, 2015
Clinical News

CureXcell: Phase III data

...a Phase III trial of CureXcell to treat diabetic foot ulcers are expected in October. Macrocure...
BioCentury | Aug 21, 2015
Company News

Macrocure plunges on Phase III futility analysis

Macrocure Ltd. (NASDAQ:MCUR) lost $9.07 (75%) to $2.98 on Thursday following its disclosure after market on Wednesday that a futility analysis showed CureXcell was unlikely to meet the primary endpoint of the Phase III MC-105...
BioCentury | Aug 20, 2015
Clinical News

Macrocure says CureXcell likely to fail in Phase III

...100% wound closure at 12 weeks and sustained complete closure for four additional weeks (p≤0.05). Macrocure...
...containing activated allogeneic white blood cells isolated from the peripheral blood of healthy allogeneic donors. Macrocure...
Items per page:
1 - 10 of 20